IDH1 and myasthenia gravis: Moreover, the results of ROC analysis indicated that our transcriptional risk score had encouraging sensitivity and specificity for distinguishing IDH/1p19q subtypes, WHO grades, and particular pathology subtypes, especially for discrimination of astrocytoma from oligodendroglioma or mixed glioma (MG) (Figure 4D).